Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2021

Open Access 01-12-2021 | Research

An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies

Authors: Lei Chen, Lianhua Dong, Yipeng Ma, Juntao Wang, Dongjuan Qiao, Geng Tian, Mingjun Wang

Published in: BMC Immunology | Issue 1/2021

Login to get access

Abstract

Adoptive transfer of T cells genetically engineered with a T cell receptor (TCR) is a promising cancer treatment modality that requires the identification of TCRs with good characteristics. Most T cell cloning methods involve a stringent singularization process, which necessitates either tedious hands-on operations or high cost. We present an efficient and nonstringent cloning approach based on existing techniques. We hypothesize that after elimination of most nonspecific T cells, a clonotype with high quality could outcompete other clonotypes and finally form a predominant population. This TCR identification method can be used to clone virus-specific TCRs efficiently from cancer patients and is easily adoptable by any laboratory.
Appendix
Available only for authorised users
Literature
1.
Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27:59–73.CrossRef
2.
Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59–64.CrossRef
3.
Münger K, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451–60.CrossRef
4.
Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus–induced disease. Annu Rev Immunol. 2015;33:787–821.CrossRef
5.
Zsiros E, Tsuji T, Odunsi K. Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. J Clin Oncol. 2015;33:1521–3.CrossRef
6.
Lutzky VP, et al. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin Vaccine Immunol. 2014;21:256–9.CrossRef
7.
Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676–80.CrossRef
8.
Dudley ME, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–57.CrossRef
9.
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.CrossRef
10.
Stevanović S, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33:1543.CrossRef
11.
Louis CU, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983–90.CrossRef
12.
Bollard CM, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798–808.CrossRef
13.
Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther. 2009;20:1240–8.CrossRef
14.
Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332–42.CrossRef
15.
Tran KQ, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742–51.CrossRef
16.
Draper LM, et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin Cancer Res. 2015;21:4431–9.CrossRef
17.
Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512–9.CrossRef
18.
Baker PE, GíLLÍS S, Smith KA. Monoclonal cytolytic T-cell lines. J Exp Med. 1979;149:273–8.CrossRef
19.
Mariotti, S. & Nisini, R. in T Cell Protocols. Methods in Molecular BiologyTM Vol. 514 (eds De Libero G.) 65–93 (Springer, 2009).
20.
Bernhard, H., Schmidt, B., Busch, D. H. & Peschel, C. in Adoptive Immunotherapy: Methods and Protocols, Methods Molecular Medicine Vol. 109 (eds Hoffmann MW Ludewig B) 175–184 (Springer, 2006).
21.
Dössinger G, et al. MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy. PLoS ONE. 2013;8:e61384.CrossRef
22.
Hu Z, et al. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018;132:1911–21.CrossRef
23.
Segaliny AI, et al. Functional TCR T cell screening using single-cell droplet microfluidics. Lab Chip. 2018;18:3733–49.CrossRef
24.
Xi-zhi JG, et al. Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis. Mol Ther Methods Clin Dev. 2016;3:15054.CrossRef
25.
Zhu Y, Machleder E, Chenchik A, Li R, Siebert P. Reverse transcriptase template switching: a SMARTTM approach for full-length cDNA library construction. Biotechniques. 2001;30:892–7.CrossRef
26.
Sebestyén Z, et al. Human TCR that incorporate CD3ζ induce highly preferred pairing between TCRα and β chains following gene transfer. J Immunol. 2008;180:7736–46.CrossRef
27.
Govers C, Sebestyén Z, Coccoris M, Willemsen RA, Debets R. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010;16:77–87.CrossRef
28.
Jin BY, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3:e99488.CrossRef
29.
Thomas S, et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol. 2007;179:5803–10.CrossRef
30.
Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231–8.CrossRef
31.
Nair SK, et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res. 2014;20:2684–94.CrossRef
32.
Watanabe K, Goodrich J, Li C, Agha M, Greenberg P. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238–41.CrossRef
33.
Inderberg EM, Wälchli S. Long-term surviving cancer patients as a source of therapeutic TCR. Cancer Immunol Immunother. 2020;69:859–65.CrossRef
34.
Kamphorst AO, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114:4993–8.CrossRef
35.
Plon SE, et al. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008;358:539–41.CrossRef
36.
Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother. 2005;28:53.CrossRef
37.
Marcinkowski B, et al. Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1. J Immunother Cancer. 2019;7:1–9.CrossRef
38.
Howie B, et al. High-throughput pairing of T cell receptor α and β sequences. Sci Transl Med. 2015;7:301ra131.CrossRef
39.
Han A, Glanville J, Hansmann L, Davis MM. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol. 2014;32:684–92.CrossRef
Metadata
Title
An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies
Authors
Lei Chen
Lianhua Dong
Yipeng Ma
Juntao Wang
Dongjuan Qiao
Geng Tian
Mingjun Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-021-00455-3

Other articles of this Issue 1/2021

BMC Immunology 1/2021 Go to the issue

Research

Transmembrane signaling molecules play a key role in the pathogenesis of IgA nephropathy: a weighted gene co-expression network analysis study

Research

PI3Kδ inhibition prevents IL33, ILC2s and inflammatory eosinophils in persistent airway inflammation

Research

Phenotypic and immune functional profiling of patients with suspected Mendelian Susceptibility to Mycobacterial Disease in South Africa

Research article

Neutrophil extracellular traps are present in the airways of ENaC-overexpressing mice with cystic fibrosis-like lung disease

Research

Angiopoietin 1 release from human neutrophils is independent from neutrophil extracellular traps (NETs)

Research article

Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet’s disease patients receiving immunomodulatory treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits